Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
NCT06423599 on ClinicalTrials.gov · last registry update 2026-06-23
Recruiting now, toward 100 participants. Due to report 30 December 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Peak oxygen uptake. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 30 April 2024 — 2 years so far. semaglutide is approved in the US, but not for heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P2/P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Jens D Hove, MD,PHD
- Sponsor type
- Other
- Enrollment
- 100
- Started
- 2024-04-30
- Primary completion
- 2027-12-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Peak oxygen uptake
Conditions studied
Heart Failure With Reduced Ejection Fraction · Obesity · Weight Loss · Chronic Heart Failure
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.